Following the €1.9 billion (US$2.16 billion) purchase of The Spectranetics Corporation by Royal Philips, Ra Medical Systems has announced the appointment of two new members to the company’s board of directors.
This also follows the recent FDA market clearance and commercial launch of Ra Medical Systems’ revolutionary DABRA system for the treatment of peripheral artery disease. Joining the board are Maurice Buchbinder, an internationally recognised interventional cardiologist, and Martin Colombatto, a veteran electronics industry executive and venture capitalist.
“Ra Medical Systems is delivering a pivotal device to the endovascular industry at just the right time, as catheter-based revascularisation of occluded arteries has been an ongoing challenge for many decades,” added Buchbinder. “I am certain that DABRA will become the standard of care for treatment well beyond peripheral circulation. DABRA is a product that addresses a truly unmet clinical need.”
“I am very impressed with the manner in which the founders and management team have systematically built a world-class medical device company with minimal outside capital,” said Colombatto. “I believe in the disruptive nature of Ra Medical Systems’ products and have joined the board to help drive the company’s growth, particularly in the removal of arterial blockages, which is a huge market.”